Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33)
- Target
- ADAM33
- Molecular classification
- Enzyme (metalloproteinase), Type I transmembrane protein, Disintegrin and metalloproteinase (ADAM) family
01
Overview
Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33) is a type I transmembrane zinc-dependent metalloprotease and a member of the ADAM family, structurally related to snake venom disintegrins. Primarily expressed in mesenchymal cells including airway fibroblasts, myofibroblasts, and smooth muscle cells, ADAM33 has a structure featuring pro-metalloprotease-like, disintegrin-like, cysteine-rich, EGF-like, and cytoplasmic domains. Genetic studies have identified ADAM33 as the first asthma-susceptibility gene linked to bronchial hyperresponsiveness, with polymorphisms associated with asthma in many populations. Its biological functions include modulating cell adhesion, proliferation, differentiation, and promoting angiogenesis. ADAM33 is strongly implicated in airway remodeling in asthma, acting at the interface of structural and inflammatory pathways, though its precise function and mechanisms in disease are still being investigated.
- Other names
- ADAM33C20orf153UNQ873/PRO1891DKFZp434K0521dJ964F7.1DJ964F7.1a disintegrin and metalloprotease 33a disintegrin and metalloproteinase domain 33disintegrin and reprolysin metalloproteinase family protein
02
Mechanism of action
Therapeutic mechanism unspecified, as no drugs are known/approved to directly target ADAM33.
03
Biological functions
Cell-cell interactionCell-matrix interactionProteolysisCell adhesionSignal transductionCell proliferation and differentiationAngiogenesisAirway remodeling (implicated)
04
Disease associations
AsthmaBronchial hyperresponsivenessAirway remodelingPotential role in other inflammatory airway diseases
05
Safety considerations
Potential challenges in selectively inhibiting ADAM33 due to expression in multiple tissue typesUnknown safety profile for ADAM33 inhibition, as there are no clinical inhibitors in use
06
Biomarkers
ADAM33 gene/protein expression as a biomarker for asthma susceptibility, airway remodeling, and response to environmental exposure
Beyond the preview
Go deeper on Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Disintegrin and metalloproteinase domain-containing protein 33 (ADAM33).